Alkermes
ALKS · Pharmaceuticals
$43.63
1.2%Indivior
INDV · Pharmaceuticals
$34.47
2.4%The short version
- Alkermes is the larger business, with $1.5B of revenue in fiscal 2025 against $1.2B for Indivior.
- Indivior grew revenue faster (4.3%, against −5.3%).
- Indivior kept more of each dollar of sales as operating profit (21.2% operating margin, against 17.2% operating margin).
- Alkermes turned more of its sales into free cash flow (32.6% FCF margin, against −7.5% FCF margin).
- Investors pay more for each dollar of Alkermes’s earnings: a P/E of 114.8x against 12.4x for Indivior.
| Latest fiscal year | ALKS · FY25 | INDV · FY25 |
|---|---|---|
| Size | ||
| Market cap | $7.6B | $4.3B |
| Revenue | $1.5B | $1.2B |
| Free cash flow | $480M | −$93.0M |
| Net income | $242M | $210M |
| Growth | ||
| Revenue growth | −5.3% | 4.3% |
| 5-year growth | 7.3% | — |
| Share count change | −0.3% | −3.8% |
| Profitability | ||
| Gross margin | 86.7% | 80.2% |
| Operating margin | 17.2% | 21.2% |
| Net margin | 16.4% | 17.0% |
| FCF margin | 32.6% | −7.5% |
| Return on capital | — | — |
| Return on equity | 14.7% | — |
| Balance sheet | ||
| Net debt | — | $124M |
| Net debt / EBITDA | — | 0.5x |
| Dividends and buybacks | $0.0M | $11.0M |
| Valuation & quality | ||
| P/E | 114.8x | 12.4x |
| Piotroski F-score | — | 4 |
FY16
ALKS $746M
INDV —
FY17
ALKS $903M
INDV —
FY18
ALKS $1.1B
INDV —
FY19
ALKS $1.2B
INDV —
FY20
ALKS $1.0B
INDV —
FY21
ALKS $1.2B
INDV $791M
FY22
ALKS $1.1B
INDV $901M
FY23
ALKS $1.7B
INDV $1.1B
FY24
ALKS $1.6B
INDV $1.2B
FY25
ALKS $1.5B
INDV $1.2B
ALKS
INDV
FY16
ALKS −28.0%
INDV —
FY17
ALKS −16.4%
INDV —
FY18
ALKS −9.1%
INDV —
FY19
ALKS −15.0%
INDV —
FY20
ALKS −10.8%
INDV —
FY21
ALKS 8.3%
INDV 26.9%
FY22
ALKS −0.6%
INDV −9.0%
FY23
ALKS 24.9%
INDV −13.9%
FY24
ALKS 27.0%
INDV 3.2%
FY25
ALKS 17.2%
INDV 21.2%
ALKS
INDV
FY16
ALKS −$107M
INDV —
FY17
ALKS −$32.1M
INDV —
FY18
ALKS $29.9M
INDV —
FY19
ALKS −$18.9M
INDV —
FY20
ALKS $40.6M
INDV —
FY21
ALKS $73.7M
INDV $349M
FY22
ALKS −$17.2M
INDV −$9.0M
FY23
ALKS $353M
INDV −$308M
FY24
ALKS $406M
INDV $7.0M
FY25
ALKS $480M
INDV −$93.0M
ALKS
INDV
FY16
ALKS −15.5%
INDV —
FY17
ALKS −11.4%
INDV —
FY18
ALKS −8.0%
INDV —
FY19
ALKS −15.9%
INDV —
FY20
ALKS −11.6%
INDV —
FY21
ALKS 10.8%
INDV —
FY22
ALKS −0.6%
INDV —
FY23
ALKS 57.2%
INDV —
FY24
ALKS —
INDV —
FY25
ALKS —
INDV —
ALKS
INDV
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.